/EVFM
EVFM Stock - Evofem Biosciences, Inc.
Healthcare|BiotechnologyOTC
$0.01-3.29%
$0.00 (-3.29%) • Dec 19
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.43
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+662400.0%upside
Target: $66.25
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVFM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.01 – $0.01
TARGET (TP)$66.25
STOP LOSS$0.01
RISK/REWARD1:Infinity
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.27
52W High$0.02
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $19.36M | $18.22M | $16.84M | $8.24M | $446,000 |
| Gross Profit | $15.53M | $11.71M | $12.42M | $4.19M | $-1,203,000 |
| Gross Margin | 80.2% | 64.3% | 73.8% | 50.8% | -269.7% |
| Operating Income | $-7,676,000 | $-17,847,000 | $-84,124,000 | $-166,801,000 | $-103,624,000 |
| Net Income | $-8,860,000 | $52.98M | $-76,698,000 | $-205,192,000 | $-142,309,000 |
| Net Margin | -45.8% | 290.8% | -455.5% | -2489.0% | -31907.8% |
| EPS | $-0.09 | $10.36 | $-164.59 | $-2962.49 | $-3973.23 |
Company Overview
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EVFMBeat Rate
58%
Last 12 quarters
Avg Surprise
-495.7%
EPS vs Estimate
Beats / Misses
7/5
Last 12 quarters
Latest EPS
$-0.01
Q4 2025
EPS Surprise History
Q1 24
+27.9%
$-0.44vs$-0.61
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 13, 2025 | — | $-0.01 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-0.02 | — | — |
Q2 2025 | May 15, 2025 | — | $0.00 | — | — |
Q1 2025 | Mar 24, 2025 | — | $-0.03 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.02 | — | — |
Q3 2024 | Aug 14, 2024 | — | $0.00 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.16 | — | — |
Q1 2024 | Mar 27, 2024 | $-0.61 | $-0.44 | +27.9% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-7.50 | $0.10 | +101.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-10.00 | $-5.43 | +45.7% | ✓ BEAT |
Q2 2023 | Jun 16, 2023 | $-15.00 | $-1.85 | +87.7% | ✓ BEAT |
Q1 2023 | Mar 2, 2023 | $-0.21 | $-8.46 | -3930.8% | ✗ MISS |
Q1 2023 | Jan 6, 2023 | $-0.25 | $-5.00 | -1900.0% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-126.25 | $-571.25 | -352.5% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-373.75 | $-360.00 | +3.7% | ✓ BEAT |
Q1 2022 | Mar 3, 2022 | $-431.03 | $-618.44 | -43.5% | ✗ MISS |
Q4 2021 | Nov 15, 2021 | $-562.22 | $-543.48 | +3.3% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-655.92 | $-506.00 | +22.9% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-918.29 | $-1049.48 | -14.3% | ✗ MISS |
Frequently Asked Questions about EVFM
What is EVFM's current stock price?
Evofem Biosciences, Inc. (EVFM) is currently trading at $0.01 per share. The stock has moved -3.29% today.
What is the analyst price target for EVFM?
The average analyst price target for EVFM is $66.25, based on 1 analyst.
What sector is Evofem Biosciences, Inc. in?
Evofem Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is EVFM's market cap?
Evofem Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does EVFM pay dividends?
No, Evofem Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBICTF
Biocure Technology Inc.
$0.01
Mkt Cap: $0.0B
BINP
Bionoid Pharma, Inc.
$0.03
Mkt Cap: $0.0B
BIOR
Biora Therapeutics, Inc.
$0.22
Mkt Cap: $0.0B
BMMJ
Body and Mind Inc.
$0.00
Mkt Cap: $0.0B
BPTH
Bio-Path Holdings, Inc.
$0.07
Mkt Cap: $0.0B
CAIHF
Chia Tai Enterprises International Limited
$0.28
Mkt Cap: $0.2B
CTVEF
Certive Solutions Inc.
$0.00
Mkt Cap: $0.0B
ISCO
International Stem Cell Corporation
$0.14
Mkt Cap: $0.0B
MRZM
Marizyme, Inc.
$0.00
Mkt Cap: $0.0B
UNBX
Unity Biotechnology, Inc.
$0.06
Mkt Cap: $0.0B
Explore stocks similar to EVFM for comparison